HK1189384A1 - 吲哚、吲唑衍生物或其鹽 - Google Patents

吲哚、吲唑衍生物或其鹽

Info

Publication number
HK1189384A1
HK1189384A1 HK14102435.3A HK14102435A HK1189384A1 HK 1189384 A1 HK1189384 A1 HK 1189384A1 HK 14102435 A HK14102435 A HK 14102435A HK 1189384 A1 HK1189384 A1 HK 1189384A1
Authority
HK
Hong Kong
Prior art keywords
indole
salt
indazole derivative
indazole
derivative
Prior art date
Application number
HK14102435.3A
Other languages
English (en)
Inventor
北出誠
大久保秀
吉村千穗子
Original Assignee
大鵬藥品工業株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大鵬藥品工業株式會社 filed Critical 大鵬藥品工業株式會社
Publication of HK1189384A1 publication Critical patent/HK1189384A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK14102435.3A 2011-01-07 2014-03-11 吲哚、吲唑衍生物或其鹽 HK1189384A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011002147 2011-01-07
PCT/JP2012/050140 WO2012093707A1 (ja) 2011-01-07 2012-01-06 新規インドール、インダゾール誘導体又はその塩

Publications (1)

Publication Number Publication Date
HK1189384A1 true HK1189384A1 (zh) 2014-06-06

Family

ID=46457557

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14102435.3A HK1189384A1 (zh) 2011-01-07 2014-03-11 吲哚、吲唑衍生物或其鹽

Country Status (14)

Country Link
US (1) US9120780B2 (zh)
EP (1) EP2662367B1 (zh)
JP (1) JP5865844B2 (zh)
KR (1) KR20140025326A (zh)
CN (1) CN103402995B (zh)
AU (1) AU2012204650A1 (zh)
BR (1) BR112013017416A2 (zh)
CA (1) CA2834101A1 (zh)
ES (1) ES2589557T3 (zh)
HK (1) HK1189384A1 (zh)
MX (1) MX2013007937A (zh)
RU (1) RU2013136861A (zh)
TW (1) TW201309672A (zh)
WO (1) WO2012093707A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1013999B1 (pt) 2009-07-10 2020-06-02 Taiho Pharmaceutical Co., Ltd. Composto de azabiciclo e um sal deste, produto farmacêutico e composição farmacêutica compreendendo dito composto e uso do mesmo para tratar câncer
CN105793421A (zh) * 2013-10-02 2016-07-20 大鹏药品工业株式会社 耐性突变型90kDa热休克蛋白质
CN104744459A (zh) * 2013-12-27 2015-07-01 中国药科大学 吡啶并吡啶酮及其衍生物的合成方法
DE102014106987A1 (de) * 2014-02-14 2015-08-20 Hartmut Yersin Organische TADF-Moleküle mit sterischer Behinderung am Donator und am Akzeptor für opto-elektronische Vorrichtungen
DE102014106986B4 (de) * 2014-02-14 2023-10-12 Samsung Display Co., Ltd. Organische Moleküle mit kleinen Triplett-Singulett-Energieabständen für eine effektive verzögerte Fluoreszenz zur Anwendung in opto-elektronischen Vorrichtungen
CN117003754A (zh) * 2022-04-28 2023-11-07 腾讯科技（深圳）有限公司 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57203068A (en) 1981-06-08 1982-12-13 Teikoku Hormone Mfg Co Ltd Novel 1-phenylisoquinoline derivative
AR028782A1 (es) 2000-07-05 2003-05-21 Taisho Pharmaceutical Co Ltd Derivados heterociclicos tetrahidropiridino o piperidino
MX2008003202A (es) * 2005-09-16 2008-03-25 Serenex Inc Derivados de carbazol.
RS53446B (en) * 2006-05-25 2014-12-31 Synta Pharmaceuticals Corp. TRIAZOLE UNITS MODULATING HSP90 ACTIVITY
WO2008024978A2 (en) * 2006-08-24 2008-02-28 Serenex, Inc. Tetrahydroindolone and tetrahydroindazolone derivatives
WO2008026704A1 (fr) 2006-08-31 2008-03-06 Kyowa Hakko Kogyo Co., Ltd. Dérivé d'isoquinoline
CA2705318C (en) 2007-11-15 2013-12-31 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
EP2229381A1 (en) * 2007-12-06 2010-09-22 Schering Corporation Gamma secretase modulators
FR2928645A1 (fr) 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
GB0807910D0 (en) 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
AR075874A1 (es) * 2009-03-19 2011-05-04 Sanofi Aventis Derivados de indazol inhibidores de hsp90 composiciones que los contienen y utilizacion
BRPI1013999B1 (pt) 2009-07-10 2020-06-02 Taiho Pharmaceutical Co., Ltd. Composto de azabiciclo e um sal deste, produto farmacêutico e composição farmacêutica compreendendo dito composto e uso do mesmo para tratar câncer

Also Published As

Publication number Publication date
MX2013007937A (es) 2013-11-01
AU2012204650A1 (en) 2013-08-01
EP2662367A4 (en) 2014-06-25
WO2012093707A1 (ja) 2012-07-12
EP2662367A1 (en) 2013-11-13
RU2013136861A (ru) 2015-02-20
TW201309672A (zh) 2013-03-01
US9120780B2 (en) 2015-09-01
CN103402995A (zh) 2013-11-20
CN103402995B (zh) 2016-08-31
EP2662367B1 (en) 2016-08-17
ES2589557T3 (es) 2016-11-15
CA2834101A1 (en) 2012-07-12
US20130289072A1 (en) 2013-10-31
BR112013017416A2 (pt) 2019-09-24
JP5865844B2 (ja) 2016-02-17
JPWO2012093707A1 (ja) 2014-06-09
KR20140025326A (ko) 2014-03-04

Similar Documents

Publication Publication Date Title
HRP20180646T1 (hr) Dispiropirolidinski derivat
HK1199840A1 (zh) 降伊波加因碱鹽非溶劑化物
EP2669285A4 (en) PYRAZOLOPYRIDINE DERIVATIVE OR PHARMACEUTICALLY UNINTENTIONAL SALT OF WHICH
EP2669271A4 (en) INDOLE DERIVATIVE AND PHARMACEUTICAL ACCEPTABLE SALT THEREOF
ZA201403000B (en) Azole Derivative
EP2687531A4 (en) TETRAHYDROCARBOLINE DERIVATIVE
HK1189384A1 (zh) 吲哚、吲唑衍生物或其鹽
HK1202860A1 (zh) 新的 -取代的吲唑衍生物
EP2740730A4 (en) DIBENZOOXEPINE DERIVATIVE
EP2522657A4 (en) indole derivative
ZA201404539B (en) Phenylpyrrole derivative
GB201217285D0 (en) Indole derivatives
IL236406A0 (en) A consequence of indole carboxamide
HK1189580A1 (zh) 吡咯衍生物
HK1198033A1 (zh) -雜環取代醯胺衍生物
IL225393A0 (en) History of Indole
EP2684878A4 (en) DIPYRIDYLAMINE DERIVATIVE
GB201109154D0 (en) Salt shaker
GB201108800D0 (en) Salt shaker

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210104